Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma.
An increased glucose metabolic rate is observed with various degrees of intensity in different subtypes of aggressive lymphomas. [(18)F]Fluorodeoxyglucose (FDG)-positron emission tomography (PET; FDG-PET) allows functional imaging of this phenomenon through 3-dimensional tomographic slices, which are now easily fused with computed tomography (CT) images. [(18)F]Fluorodeoxyglucose-PET staging appears superior to conventional staging modalities for detecting nodal and extranodal lymphoma. When performed after first-line chemotherapy, FDG-PET is more efficient than CT and conventional diagnostic methods to predict the disease outcome. Some studies have reported that the relapse rate is 100% in patients with positive PET findings after treatment and 17% in patients with negative PET findings. This imaging modality can also assess early response after 1-2 cycles of chemotherapy, thus identifying responders from patients whose cancer will fail to respond to first-line therapy or will relapse shortly after having exhibited a partial or complete remission. [(18)F]Fluorodeoxyglucose-PET also seems useful for an accurate selection of patients who will benefit from highly intensive treatment.
Meignan
Michel
M
Department of Nuclear Medicine, Hopital Henri Mondor, Creteil, France. michel.meignan@hmn.ap-hop-paris.fr
Haioun
Corinne
C
Itti
Emmanuel
E
Rahmouni
Alain
A
Reyes
Felix
F
D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage*; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy; D049268:Positron-Emission Tomography / Q000379:methods; D011859:Radiography; D019275:Radiopharmaceuticals / Q000008:administration & dosage*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18